Spots Global Cancer Trial Database for Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Official Title: Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study ID: NCT00831597
Conditions
Study Description
Brief Summary: A phase II trial to evaluate the efficacy and safety of combination bendamustine and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. It is hypothesized that the BR combination will produce at least a 70% overall response rate.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pharmatech Oncology Study Site, Beverly Hills, California, United States
Pharmatech Oncology Study Site, Fountain Valley, California, United States
Pharmatech Oncology Study Site, Oxnard, California, United States
Pharmatech Oncology Study Site, Washington, District of Columbia, United States
Pharmatech Oncology Study Site, Washington, District of Columbia, United States
Pharmatech Oncology Study Site, Boynton Beach, Florida, United States
Pharmatech Oncology Study Site, Brooksville, Florida, United States
Pharmatech Oncology Study Site, Gainesville, Florida, United States
Pharmatech Oncology Study Site, Titusville, Florida, United States
Pharmatech Oncology Study Site, Joliet, Illinois, United States
Pharmatech Oncology Study Site, Lafayette, Indiana, United States
Pharmatech Oncology Study Site, Muncie, Indiana, United States
Pharmatech Oncology Study Site, Dubuque, Iowa, United States
Pharmatech Oncology Study Site, Paducah, Kentucky, United States
Pharmatech Oncology Study Site, York, Maine, United States
Pharmatech Oncology Study Site, Jackson, Mississippi, United States
Pharmatech Oncology Study Site, Chesterfield, Missouri, United States
Pharmatech Oncology Study Site, Cherry Hill, New Jersey, United States
Pharmatech Oncology Study Site, Phillipsburg, New Jersey, United States
Pharmatech Oncology Study Site, Bay Shore, New York, United States
Pharmatech Oncology Study Site, Bronx, New York, United States
Pharmatech Oncology Study Site, East Setauket, New York, United States
Pharmatech Oncology Study Site, Akron, Ohio, United States
Pharmatech Oncology Study Site, Columbus, Ohio, United States
Pharmatech Oncology Study Site, Bethlehem, Pennsylvania, United States
Pharmatech Oncology Study Site, Gettysburg, Pennsylvania, United States
Pharmatech Oncology Study Site, Hilton Head, South Carolina, United States
Pharmatech Oncology Study Site, Germantown, Tennessee, United States
Pharmatech Oncology Study Site, Austin, Texas, United States
Pharmatech Oncology Study Site, Corpus Christi, Texas, United States
Pharmatech Oncology Study Site, Fort Worth, Texas, United States
Pharmatech Oncology Study Site, Lubbock, Texas, United States
Pharmatech Oncology Study Site, Richardson, Texas, United States
Contact Details
Name: Jeffrey L Vacirca, MD, FACP
Affiliation: University Hospital, Stony Brook North Shore Hematology/Oncology Associates
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
